METHYL 3-METHYL-4-OXOCYCLOHEXANECARBOXYLATE, 95.0%, 250mg

1-Benzyl 2-methyl (2S,4R)-4-((tert-butoxycarbonyl)amino)pyrrolidine-1,2-dicarboxylate, 97%, 250mg

tert-butyl 4-(aminomethyl)-4-hydroxy-1-azepanecarboxylate, 95.0%, 1g

2,6-Dichloro-N,N-dimethylpyridin-4-amine, 95.0%, 1g

5-Oxononanedioic acid, 97%, 250mg

Isopentyl 2-hydroxybenzoate, 95.0%, 500g

4-methoxybenzyl hydrazinecarboxylate, 98%, 5g

4-chloro-6-pyridin-4-ylpyrimidine, 95.0%, 500mg

2-(2-Methyl-2H-tetrazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 95.0%, 1g

2'-Hydroxy-3',5'-dimethylacetophenone>98.0%(GC)5g

Boc-D-Glutamic acid 1-fluorenylmethylester, 97.0%, 5g

Plan phase PLPHi S40x/0.65 infinity corrected IOS objective. Working distance 0.66 mm

5-Chloropyrazolo[1,5-a]pyrimidine-3-carbaldehyde, 97%, 100mg